Samsung Biologics - Wikipedia
Samsung Biologics Plans to Accelerate the Opening of its New Fifth Plant
Samsung Biologics eyes IPO by year-end - Nikkei Asia
Samsung BioLogics Plant 3 Starts Production
IPO puts value of Samsung BioLogics at $8.2B | Fierce Pharma
Samsung BioLogics sees sales rise but profit fall as it continues expansion | Fierce Pharma
Samsung Biologics Sets Sights on Net Zero Transition as New Plant Revs Up
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Samsung Biologics reports earnings surprise in Q2 on vaccine addition - Pulse by Maeil Business News Korea
Samsung Biologics to double production by 2032; eyes ADCs, M&As - KED Global
Samsung Biologics Accelerates Timeline Of New Fifth Plant | Contract Pharma
Samsung Biologics | Incheon
Samsung Biologics Aims to Create Super-wide Gap in CDMO Field - Businesskorea
PharmaBoardroom - Samsung Biologics
Our Story | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics reports an 18.8-percent rise in net profit
Pfizer and Samsung Biologics ink biosimilars manufacturing deal
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics | The Leading Global CDMO with End-to-End Services
Samsung Biologics signs $409 mil. CMO deal with Pfizer - The Korea Times
Our Story | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics' P4 Super Plant, Songdo, South Korea
Samsung Biologics Page 1 of 0 | ISM
